World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
51589
World Ranking
10260
National Ranking
987

Research.com Recognitions

  • Fellow of The Academy of Medical Sciences, United Kingdom
  • Fellow of The Academy of Medical Sciences, United Kingdom

Overview

Jonathan A. Ledermann is affiliated with University College London in the United Kingdom. Their research primarily spans the field of Medicine, with significant contributions to subfields such as Reproductive Medicine, Oncology, Genetics, Obstetrics and Gynecology, and Pulmonary and Respiratory Medicine.

The scientist has authored numerous papers, focusing especially on cancer treatments and associated diagnostics. Key recent publications include:

  • ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma, 2020, International Journal of Gynecological Cancer
  • Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2022, Annals of Oncology
  • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer, 2020, Annals of Oncology
  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial, 2021, The Lancet Oncology
  • Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study, 2021, The Lancet Oncology

Frequent co-authors collaborating with Jonathan A. Ledermann include:

  • Amit M. Oza
  • Nicoletta Colombo
  • Clare L. Scott
  • Chunxue Bai
  • Joseph Bauer

The scientist's work is often published in several high-impact journals, such as:

  • Cancer
  • International Journal of Gynecological Cancer
  • Annals of Oncology
  • Gynecologic Oncology
  • Journal of Clinical Oncology

Main research topics addressed by their work include:

  • Ovarian cancer diagnosis and treatment
  • PARP inhibition in cancer therapy
  • Endometrial and Cervical Cancer Treatments
  • BRCA gene mutations in cancer
  • Toxin Mechanisms and Immunotoxins
  • Intraperitoneal and Appendiceal Malignancies
  • Cancer Immunotherapy and Biomarkers

Jonathan A. Ledermann was recognized as a Fellow of The Academy of Medical Sciences in the United Kingdom. Their career reflects extensive research activity and collaboration within the medical oncology community, with special emphasis on gynecologic cancers and targeted therapies.

Best Publications

  • ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.

    Nicoletta Colombo;Carien Creutzberg;Frederic Amant;Tjalling Bosse

  • A phase 3 trial of bevacizumab in ovarian cancer.

    Timothy J Perren;Ann Marie Swart;Jacobus Pfisterer;Jonathan A Ledermann

  • Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Mansoor R. Mirza;Bradley J. Monk;Jørn Herrstedt;Amit M. Oza

  • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

    MK Parmar;JA Ledermann;N Colombo;Bois A Du

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

    Nicole Concin;Xavier Matias-Guiu;Ignace Vergote;David Cibula

  • Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    J.A. Ledermann;F.A. Raja;C. Fotopoulou;A. Gonzalez-Martin

  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    N. Colombo;C. Sessa;A. du Bois;J. Ledermann

  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

    Amit M. Oza;Adrian D. Cook;Jacobus Pfisterer;Andrew Embleton

  • Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial

    Roger D James;Robert Glynne-Jones;Helen M Meadows;David Cunningham

  • Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

    Matthew T Seymour;Timothy S Maughan;Jonathan A Ledermann;Clare Topham

  • Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial

    Theo Ruers;Frits Van Coevorden;Cornelis J. A. Punt;Jean-Pierre E. N. Pierie

  • Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

    Stephanie M. de Boer;Melanie E. Powell;Linda Mileshkin;Dionyssios Katsaros

  • Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    U.A. Matulonis;R. Shapira-Frommer;A.D. Santin;A.S. Lisyanskaya

  • 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Report From the Fourth Ovarian Cancer Consensus Conference

    Gavin C.E. Stuart;Henry Kitchener;Monica Bacon;Andreas duBois

  • Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

    Jonathan A Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.

    N Colombo;N Colombo;C Sessa;A du Bois;J Ledermann

Frequent Co-Authors

Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Ursula A. Matulonis
Ursula A. Matulonis Harvard University
Michael Friedlander
Michael Friedlander University of New South Wales
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Carol Aghajanian
Carol Aghajanian Memorial Sloan Kettering Cancer Center
Iain A. McNeish
Iain A. McNeish Imperial College London
Giovanni Scambia
Giovanni Scambia Catholic University of the Sacred Heart
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA can open doors to many related healthcare fields and flexible career paths. Prospective students don’t always have to follow the traditional medical school route and, thanks to online learning, there are more accessible options than ever.

For instance, if you are considering nursing, you may wonder do all nursing schools require the teas? Some top schools offer programs without the TEAS or HESI exam requirement, making admission more attainable.

Those interested in healthcare leadership roles might look into a degree in healthcare administration, which prepares graduates for high-demand management positions in hospitals and health systems.

Registered nurses aiming to advance their practice can pursue rn to fnp bridge programs. These online bridge degrees help nurses become Family Nurse Practitioners, broadening their scope of practice.

If you have a passion for food and health, consider the best online food science degree options. These programs lead to careers in nutrition, wellness, and food safety.

Exploring these online healthcare pathways can offer flexibility and specialization, helping you build a rewarding career that fits your goals.

Best Scientists Citing Jonathan A. Ledermann

Trending Scientists